bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) and Briacell Therap (NASDAQ:BCTX – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability.
Earnings & Valuation
This table compares bioAffinity Technologies and Briacell Therap”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| bioAffinity Technologies | $9.36 million | 0.77 | -$9.04 million | ($20.96) | -0.08 |
| Briacell Therap | N/A | N/A | -$26.31 million | ($83.18) | -0.15 |
Profitability
This table compares bioAffinity Technologies and Briacell Therap’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| bioAffinity Technologies | -217.45% | -425.87% | -162.30% |
| Briacell Therap | N/A | -291.42% | -180.62% |
Institutional & Insider Ownership
1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 15.4% of Briacell Therap shares are held by institutional investors. 3.3% of bioAffinity Technologies shares are held by company insiders. Comparatively, 5.7% of Briacell Therap shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current ratings and price targets for bioAffinity Technologies and Briacell Therap, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| bioAffinity Technologies | 1 | 1 | 0 | 0 | 1.50 |
| Briacell Therap | 1 | 0 | 1 | 0 | 2.00 |
Briacell Therap has a consensus target price of $320.00, indicating a potential upside of 2,535.91%. Given Briacell Therap’s stronger consensus rating and higher possible upside, analysts plainly believe Briacell Therap is more favorable than bioAffinity Technologies.
Risk and Volatility
bioAffinity Technologies has a beta of 2.41, suggesting that its share price is 141% more volatile than the S&P 500. Comparatively, Briacell Therap has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.
Summary
Briacell Therap beats bioAffinity Technologies on 7 of the 13 factors compared between the two stocks.
About bioAffinity Technologies
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.
About Briacell Therap
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
